Skip to main content
Psychedex

6Node page

what any key link opens

psx:substance/3-meo-pcmo/claim/598d889e-5f50-4f60-a937-b79eb8a0c068

claim2026-05-09workingnot_supported

derived from · upstream

feeds · downstream

Closure of psx:substance/3-meo-pcmo/claim/598d889e-5f50-4f60-a937-b79eb8a0c068: 44 upstream, 73 downstream.

psx:substance/3-meo-pcmo/claim/598d889e-5f50-4f60-a937-b79eb8a0c068
├─ used  src/doi:10.1016/j.forsciint.2017.02.034  A non-fatal intoxication and seven deaths involving the dissociative drug 3-MeO-PCP
  ├─ informed_by  claim/f970fbc1-9f86-41ff-9512-67423919425c  Claim in history — supported
  ├─ informed_by  claim/02c37959-eeff-4d34-aa74-044fd58e8ebf  Claim in history — inconclusive  working
  ├─ informed_by  claim/ebe93617-c606-4396-ba55-99cc264dc9be  Claim in history — inconclusive  working
    ├─ used  src/doi:10.1002/dta.2213  Syntheses, analytical and pharmacological characterizations of the 'legal high' 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo) and analogues
    ├─ used  src/url:acab476d88edfe69  3-MeO-PCMo — PsychonautWiki
    ├─ used  src/doi:10.1371/journal.pone.0059334  The ketamine analogue methoxetamine and 3- and 4-methoxy analogues of phencyclidine are high affinity and selective ligands for the glutamate NMDA receptor
    ├─ used  src/doi:10.1016/j.mehy.2013.03.030  Is methoxydine a new rapid acting antidepressant for the treatment of depression in alcoholics?
    ├─ used  src/doi:10.1093/jat/bkac023  Reports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2017–2020: A Review
    ├─ used  src/doi:10.1016/j.jflm.2019.05.011  The risk of emerging new psychoactive substances: The first fatal 3-MeO-PCP intoxication in The Netherlands
    ├─ used  src/doi:10.1016/s0893-133x(98)00060-8  The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia.
    ├─ used  src/doi:10.2174/1570159X14666161018151716
    ├─ used  src/pmid:2172677  Sigma binding sites in the brain; an emerging concept for multiple sites and their relevance for psychiatric disorders
    ├─ used  src/doi:10.1016/j.forsciint.2016.12.028  3-MeO-PCP intoxication in two young men: First in vivo detection in Italy
    ├─ used  src/doi:10.3109/15563650.2015.1079325  Phencyclidine analog use in Sweden--intoxication cases involving 3-MeO-PCP and 4-MeO-PCP from the STRIDA project
    ├─ used  src/doi:10.1097/MD.0000000000018295
    ├─ used  src/doi:10.1016/j.ajpath.2015.12.014  Ketamine-Induced Apoptosis in Normal Human Urothelial Cells: A Direct, N-Methyl-d-Aspartate Receptor-Independent Pathway Characterized by Mitochondrial Stress
    ├─ used  src/doi:10.1017/s0033291719001727  New/emerging psychoactive substances and associated psychopathological consequences
    ├─ used  src/url:f246d23d56d6c12f  Schedules of Controlled Substances: Placement of 3-Methoxyphencyclidine in Schedule I (Final Rule)
    ├─ derived_from  gen/1e7e8bec-245c-48a7-8e7c-65cde3eddf18  Generation — pipeline-v5
    ├─ generated_by  pub/be34f583-daa3-4c66-be79-bf5ceb13760f  Publication — backfill
    ├─ invalidated_by  pub/af429061-042e-449f-b2b3-17727818b0a9  Publication — publish
      ├─ used  search/15636187-9e36-45ab-9121-bd4c4758aca8  Searched PubChem for "3-MeO-PCMo"
      ├─ used  search/150d15d7-c4a8-4dac-a8e4-6ee59e241fa7  Searched PubChem for "4-[1-(3-methoxyphenyl)cyclohexyl]morpholine"
      ├─ used  search/779639af-1195-4314-8078-f078a065913c  Searched PubMed for "3-MeO-PCMo morpholine arylcyclohexylamine dissociative"
      ├─ used  search/c0a43782-1e5f-47ea-b9c6-fdd85a3b177e  Searched PubMed for "methoxyphenylcyclohexylmorpholine NMDA receptor dissociative"
      ├─ used  search/4384b290-43bc-4335-bf18-acc226ac5fa6  Searched PubMed for "3-methoxyphencyclidine 3-MeO-PCP new psychoactive substance pharmacology"
      ├─ used  search/fd1e2436-a8df-4774-a8c0-4b59d5ed603d  Searched PubMed for "arylcyclohexylamine new psychoactive substance NPS dissociative analytical"
      ├─ used  search/3cf56a5d-e72d-4f8f-a4c8-136423e62ba1  Searched PubMed for "PCMo phencyclidine morpholine analogue NPS"
      ├─ used  search/35767acd-0fd2-42ae-b9ea-6adf95d6ce31  Searched Crossref for "DOI 10.1002/dta.2213"
      ├─ used  search/5c5f1ba7-47ac-491f-9fa3-e0f729bcf85c  Searched PubMed for "phencyclidine sigma receptor binding arylcyclohexylamine"
      ├─ used  search/be58a936-282e-4133-b3a6-8a3c862faedb  Searched PubMed for "3-MeO-PCP metabolism CYP"
      ├─ used  search/a380c5ae-eda8-445b-8923-4463f98b9195  Searched ClinicalTrials.gov for "3-MeO-PCMo morpholine phencyclidine"
      ├─ used  search/26d91725-81c2-4f90-ba37-b1660b2e006f  Searched WebSearch for "3-MeO-PCMo legal status scheduling DEA USA UK EU"
      ├─ used  search/748ade21-d9d2-4376-99df-2fedd180c31b  Searched WebSearch for "3-MeO-PCMo research chemical market history 2015"
      ├─ used  search/5dc00cde-240d-4df2-94a1-42901bf21c0b  Searched PsychonautWiki
      ├─ used  search/e1e11b7f-38e3-4246-8ecf-0a05f223d2c5  Searched WHO/ECDD
      ├─ used  search/cd0d94d5-45b5-4947-aab0-371fdb9c15f2  Searched OpenAlex for "arylcyclohexylamine dissociative NPS review"
      ├─ used  search/64b331a4-42bc-4f4f-87e8-2fc09e827df7  Searched OpenAlex for "methoxyphencyclidine 3-MeO-PCP forensic toxicology"
      ├─ used  search/1b7a23e9-8082-4956-8c79-f5c4e65f3f45  Searched OpenAlex for "3-MeO-PCP 3-methoxyphencyclidine toxicology pharmacology NPS"
      ├─ used  search/50673daa-4d29-4f63-86cc-4e5347e2f400  Searched Grokipedia
      ├─ used  search/3a1de0d9-f8be-48b9-93f4-1c48df5a6cb0  Searched WebSearch for "3-MeO-PCP Schedule I DEA 2025 effective date"
      ├─ invalidated_by  issue/info_card@ba24b67503fd  Issued info_card
      └─ attributed_to  human/reviewer:agent-psx
├─ informed_by  section/history.full@1
  ├─ used  version/1  Revision 1
  ├─ used  claim/b6f6790d-3a7c-46e9-9085-ffd3ca6ccaf0  Claim in summary — supported
  ├─ used  claim/0bc4bccb-5fd8-412a-9a68-1bb188fa92b7  Claim in safety — inconclusive  working
  ├─ used  claim/7c8cf094-0313-4cd2-9541-9c298a12cda7  Claim in safety — inconclusive  working
  ├─ used  claim/d1743a9e-b100-47ba-96bd-6bd06e51c882  Claim in safety — not_supported  working
  ├─ used  claim/42d1971b-26ae-488c-bcea-fac042ccbbae  Claim in safety — inconclusive  working
    ├─ derived_from  issue/notice@d64f1d67defc  Issued notice
    ├─ derived_from  issue/info_card@cc56525ee3fa  Issued info_card
    ├─ derived_from  issue/emergency@ba304cf8bf8d  Issued emergency
    ├─ revised_from  version/2  r1.a1
    ├─ informed_by  section/summary.full@1
    ├─ informed_by  section/safety.full@1
      ├─ used  claim/e63279e4-93f0-47b6-a853-ce77ef6a9269  Claim in pharmacology — supported
      ├─ used  claim/6d3aac54-0062-442c-b096-f7a262468e11  Claim in pharmacology — inconclusive  working
      ├─ used  claim/c0763718-4902-44b9-9ea5-7c44c8a98df2  Claim in summary — partially_supported
      ├─ used  claim/ffb9aa85-61df-4399-a10e-ed9751e1b011  Claim in summary — supported
      ├─ used  claim/73523d92-01df-43c7-8c4f-a25bb3904d26  Claim in pharmacology — inconclusive  working
      ├─ used  claim/a8a5b9cb-2be4-46d9-a11f-a040d0113da2  Claim in pharmacology — supported
      ├─ used  claim/ae76f344-d689-44dd-bfa5-65cc202c76b8  Claim in pharmacology — inconclusive  working
      ├─ used  claim/98ef1e60-3a94-4c13-bff7-46f526020d15  Claim in pharmacology — supported
      ├─ used  claim/f4f014ea-73d0-4e3e-a658-a96a2c23fad6  Claim in chemistry — inconclusive  working
      ├─ used  claim/1b95f367-8b82-4002-84b6-2c4f3b94a68c  Claim in chemistry — supported
      ├─ used  claim/ea374f05-f86a-4edd-a061-17ba4a8a92c6  Claim in chemistry — supported
      ├─ used  claim/b3f99a77-58b2-4309-8ec7-c53e8816f3f1  Claim in chemistry — partially_supported
      ├─ used  claim/f0e20460-2fb7-46df-a73a-0daf9c14962e  Claim in chemistry — supported
      ├─ used  claim/8637e1e8-900f-454d-a833-deea99b68733  Claim in receptor-pharmacology — supported
      ├─ used  claim/dbe7e3e5-5f3b-4cb2-b390-6211b6835e6b  Claim in receptor-pharmacology — partially_supported
      ├─ used  claim/40b86f1c-8e3a-4acf-9918-24ad394f2961  Claim in receptor-pharmacology — supported
      ├─ used  claim/bad89a2c-c842-420d-b53c-c82dd87a8c74  Claim in receptor-pharmacology — supported
      ├─ used  claim/39c3da89-42f9-4c69-88de-caa69bdd4e0c  Claim in pharmacokinetic-detail — supported
      ├─ used  claim/11671e95-adf6-4315-9e37-38ac0a5fe423  Claim in clinical-evidence — supported
      ├─ used  claim/417b309d-ee02-4233-86af-f408a43849bf  Claim in comparative-pharmacology — supported
      ├─ used  claim/02278ce9-6947-4037-b0db-832ab3e28421  Claim in comparative-pharmacology — partially_supported
      ├─ used  claim/77b7e075-f6e5-4233-9aaa-7a8fdd27a06d  Claim in comparative-pharmacology — supported
      ├─ used  claim/17d6dda9-610e-4a77-a9f6-7f7bf12a4fbd  Claim in neuroscience — supported
      ├─ used  claim/2d65bcf0-8ff9-469a-968b-dfdf379edfcb  Claim in summary — supported
      ├─ used  claim/03433f20-b4b5-4f20-8937-4ea2610d8533  Claim in pharmacology — supported
      ├─ used  claim/4e18cbb3-0c7d-482d-a1ed-42ed14b163a7  Claim in pharmacology — supported
      ├─ used  claim/8ab9877d-a854-4424-ba2a-e8fa2348e961  Claim in safety — supported
      ├─ used  claim/2a6313a8-95e7-48f9-ab5e-861f9c8286e8  Claim in receptor-pharmacology — supported
      ├─ used  claim/b99bc8df-8110-482f-8fc1-2998d210e31d  Claim in receptor-pharmacology — supported
      ├─ used  claim/a856b2cf-9214-42c5-9dee-9f0b306e0287  Claim in comparative-pharmacology — inconclusive  working
      ├─ used  claim/1198eaaa-5035-4264-a006-5ab87ab072f2  Claim in summary — supported
      ├─ used  claim/5c826ff4-9756-40bc-8bb1-a8be0d5786e3  Claim in pharmacology — supported
      ├─ used  claim/de1f21d4-5f24-4e51-9df8-2c0e419f995a  Claim in receptor-pharmacology — supported
      ├─ used  claim/0b90fc9b-5467-4b04-a8db-0ad22cb7f0a4  Claim in summary — inconclusive  working
      ├─ used  claim/b3de182f-4ba7-43fd-a0ff-0ad84ed19220  Claim in clinical-evidence — inconclusive  working
      ├─ used  claim/e0e5322a-f884-4960-93e0-a96d0a555f97  Claim in safety — inconclusive  working
      ├─ used  claim/fdb7e1a8-7dc5-44a5-b6a3-9e06252803cf  Claim in summary — supported
      ├─ used  claim/74d388e3-a735-41a5-87b6-29869713523f  Claim in safety — supported
      ├─ used  claim/6fa16d0c-6a91-49a5-88d6-ea2246221a55  Claim in safety — supported
      ├─ used  claim/af6b8d71-b238-4b01-ba2c-d5e4116c8719  Claim in pharmacology — supported
      ├─ used  claim/5e3f3c7d-169a-4bbc-aa59-a37e4357fbe6  Claim in safety — supported
      ├─ used  claim/8827341d-bd4e-44f0-baab-077982f65d31  Claim in safety — supported
      ├─ used  claim/3a3fbbe7-7091-4a6b-bfc5-938f56bcc48e  Claim in neuroscience — supported
      ├─ used  claim/31277fbf-a939-4c0e-9064-1f5b23dd7265  Claim in neuroscience — supported
      ├─ used  claim/6e45ef51-5ac2-4c25-899b-2bfb5c84a59d  Claim in pharmacokinetic-detail — supported
      ├─ used  claim/c84ca688-9806-4f92-8385-01a6d03abef3  Claim in pharmacology — supported
      ├─ used  claim/3f6d9b73-97a4-4d6d-aeb4-6ea20d888a02  Claim in pharmacology — inconclusive  working
      ├─ used  claim/a5d4245e-0772-4d8c-8f22-c2f0ad548ad5  Claim in pharmacology — inconclusive  working
      ├─ used  claim/b721cf29-21b6-4f49-b8ba-1c9a2cbcc147  Claim in safety — supported
      ├─ used  claim/15e12b61-9cb1-4073-a865-264819765ec6  Claim in safety — inconclusive  working
      ├─ used  claim/5f7e1e22-7646-4f32-a9ca-d27d83cebe63  Claim in pharmacokinetic-detail — supported
      ├─ used  claim/5fdfc3f2-182e-4be1-9da5-486a105bd387  Claim in pharmacokinetic-detail — inconclusive  working
      ├─ used  claim/489cf141-548a-49a0-8d5a-322ae685955e  Claim in pharmacokinetic-detail — inconclusive  working
      ├─ used  claim/2c4a7d95-4980-42e3-bf09-901d4e019183  Claim in receptor-pharmacology — supported
      ├─ used  claim/e6623ce7-6440-4f92-b572-4e52fac912b9  Claim in safety — supported
      ├─ used  claim/a119dbbb-45ba-49b5-8a0a-5c610a2431c1  Claim in safety — partially_supported
      ├─ used  claim/4d0361c8-563b-4b27-9b1f-eaeeff884865  Claim in safety — supported
      ├─ used  claim/691ae1d5-ff5f-4a34-885c-c0fc2b4fb174  Claim in safety — inconclusive  working
      ├─ used  claim/3e79f88f-9613-437e-a77d-7430b2934dd2  Claim in safety — supported
      └─ used  claim/6eb2eb3e-ae78-472a-8542-0d7633c7ebd8  Claim in safety — supported
… closure truncated at 200 nodes

indented by distance from this node, not by parentage

1Provenance card

the boundary, as counts

Sources

1613 with DOI

1 strong · 9 moderate · 6 weak

Compilations

32026-05-09T09:51:53.841Z

pipeline-v5 · prompt hash not recorded — run predates 2026-09

Decisions

33last ruled 2026-10-02

0 awaiting a ruling

Issued documents

42026-10-02T12:19:00.238Z

notice · info card · emergency

Searches

201 with no results

queries and counts on the build

Claims checked

6948 supported

48 supported · 21 not

Correspondence

0received

consent field ships in Phase 4

Edges

224

derivations recorded for this entity

Complete over 16 sources, 3 compilations, and 33 decisions.Not here: the private journal (never).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/3-meo-pcmo/archive

2Build

one panel per compilation run

generation run 2026-05-09

9 min failedmodel not recordedplan not recordedrun/be1f19e8…

research

no artifact

draft

no artifact

audit

no artifact

verify

no artifact

simplify

no artifact

publish

no artifact

Selection

results seen0
selected by the model0
consumed as sources15

Verification

claims checked0
supported0
partially supported0
not supported0
inconclusive0
  • record
  • seen / partial
  • working

The model's own caveats

none raised on this run

Reproduce

inputs
15 source keys (listed under Sources)
plan
not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
model
not recorded
streams
none — agent transcripts are persisted from 2026-09 onward

generation run 2026-05-09

13 min failedmodel not recordedplan not recordedrun/badf4f9e…

research

no artifact

draft

no artifact

audit

no artifact

verify

no artifact

simplify

no artifact

publish

no artifact

Selection

results seen0
selected by the model0
consumed as sources15

Verification

claims checked0
supported0
partially supported0
not supported0
inconclusive0
  • record
  • seen / partial
  • working

The model's own caveats

none raised on this run

Reproduce

inputs
15 source keys (listed under Sources)
plan
not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
model
not recorded
streams
none — agent transcripts are persisted from 2026-09 onward

generation run 2026-05-09

804 min failedmodel pipeline-v5plan not recordedrun/cecde04b…

research

citationsRegistryrecordresearchOutputworking

draft

articleDraftworking

audit

articleAuditedworking

verify

verificationResultworking

simplify

articleSimplifiedworking

publish

runMetarecordrunSummaryrecord

Selection

results seen82
selected by the model32
consumed as sources15

Verification

claims checked69
supported43
partially supported5
not supported2
inconclusive19
  • record
  • seen / partial
  • working

The model's own caveats

  • sparse_evidence
  • structural_inference
  • safety_data_unverified

Reproduce

inputs
15 source keys (listed under Sources)
plan
not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
model
pipeline-v5
streams
none — agent transcripts are persisted from 2026-09 onward
20 searches — query, source, results, what was kept and why
20 searches for this run
#sourcequeryseenkeptrationale
1PubChem4-[1-(3-methoxyphenyl)cyclohexyl]morpholine11Confirming chemical identity by systematic name
2PubChem3-MeO-PCMo11Primary chemical identity verification
3PubMedPCMo phencyclidine morpholine analogue NPS21NMDAR inhibition assay paper relevant to class pharmacology
4PubMed3-methoxyphencyclidine 3-MeO-PCP new psychoactive substance pharmacology44These 3-MeO-PCP studies provide class-level pharmacology and toxicology context for 3-MeO-PCMo
5PubMed3-MeO-PCMo morpholine arylcyclohexylamine dissociative11This is the only published pharmacological study specifically on 3-MeO-PCMo
6PubMedmethoxyphenylcyclohexylmorpholine NMDA receptor dissociative10——
7PubMedarylcyclohexylamine new psychoactive substance NPS dissociative analytical42Context on arylcyclohexylamine NPS class toxicology and forensic identification
8WebSearch3-MeO-PCMo legal status scheduling DEA USA UK EU102Legal status for harm reduction and legal status section
9CrossrefDOI 10.1002/dta.221311DOI verification of primary paper
10PubMedphencyclidine sigma receptor binding arylcyclohexylamine32Sigma receptor binding context for arylcyclohexylamine class
11PsychonautWiki—12Community-consensus dose and duration data
12WebSearch3-MeO-PCMo research chemical market history 2015102Historical market emergence data
13ClinicalTrials.gov · absence3-MeO-PCMo morpholine phencyclidine0—Confirming absence of clinical trials
14PubMed3-MeO-PCP metabolism CYP11Metabolic pathway data for the 3-methoxyphenyl arylcyclohexylamine class
15OpenAlexarylcyclohexylamine dissociative NPS review82Class-level review context for 3-MeO-PCMo
16WHO/ECDD—1—Attempted retrieval; file could not be parsed
17OpenAlex3-MeO-PCP 3-methoxyphencyclidine toxicology pharmacology NPS82Complete metabolic pathway data and organ toxicity class context
18WebSearch3-MeO-PCP Schedule I DEA 2025 effective date101Parent compound scheduling context for US legal status assessment of 3-MeO-PCMo
19Grokipedia—14Legal status and pharmacological detail verification
20OpenAlexmethoxyphencyclidine 3-MeO-PCP forensic toxicology53Critical pharmacology (sigma receptor), fatality data, and class context
69 claims by section — every cited sentence, checked against its source
safety18 · 11 ok

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • A fatal case in the Netherlands involved a blood concentration of 152 µg/L 3-MeO-PCP in combination with amphetamine and alcohol; death was not definitively attributed to 3-MeO-PCP alone.supported

    Fatal case involving 3-MeO-PCP (152 µg/L whole blood), amphetamine, and alcohol. First fatal case in Netherlands. j.jflm.2019.05.011

  • Delirium and agitation persisted to 24 hours post-admission.supported

    Delirium/agitation at 24h. j.forsciint.2016.12.028

  • Additional non-fatal intoxication cases were documented by the STRIDA project in Sweden from mid-2013, and a case series with literature review was published from France involving two intoxication episodes in the same patient.partially supported

    Case series from Sweden STRIDA project with clinical and bioanalytical data from analytically confirmed non-fatal intoxications with 3-MeO-PCP and 4-MeO-PCP. 15563650.2015.1079325

  • Additional non-fatal intoxication cases were documented by the STRIDA project in Sweden from mid-2013, and a case series with literature review was published from France involving two intoxication episodes in the same patient.supported

    Reports 2 intoxication cases in the same patient and reviews manifestations of intoxication. md.0000000000018295

  • Urological (chronic): Ketamine-induced cystitis involves direct urothelial apoptosis through a non-NMDA receptor-mediated pathway. Whether 3-MeO-PCMo or other arylcyclohexylamines produce analogous urotoxicity with chronic use is unknown.supported

    Ketamine induces urothelial apoptosis via NMDAR-independent mechanism involving purinergic P2Y receptors and mitochondrial pathway. j.ajpath.2015.12.014

  • Claim in safety — inconclusiveinconclusiveworking →

  • Acute and persistent psychosis has been documented following 3-MeO-PCP usesupported

    NPS psychopathological consequences review including dissociatives. s0033291719001727

  • Dependence: PCP analogues demonstrate reinforcing properties in animal self-administration paradigms, driven by dopaminergic disinhibition via NMDA receptor hypofunctionsupported

    Landmark review of PCP pharmacology including NMDA receptor hypofunction and dopaminergic effects. s0893-133x(98)00060-8

  • Claim in safety — inconclusiveinconclusiveworking →

  • Every documented fatality involving 3-MeO-PCP included co-ingestion of CNS depressants — alcohol in all cases, with additional substances in somesupported

    Fatal case involving 3-MeO-PCP (152 µg/L whole blood), amphetamine, and alcohol. j.jflm.2019.05.011

  • Claim in safety — not_supportednot supportedworking →

  • Serotonergic agents: If 3-MeO-PCMo possesses meaningful SERT affinity — as documented for related PCP analogues — combination with MAO inhibitors, SSRIs, or other serotonergic drugs could potentiate serotonergic effectssupported

    Methoxetamine and PCP analogues showed appreciable affinity for serotonin transporter. journal.pone.0059334

  • Psychotic disorders (personal or family history): PCP-class NMDA antagonists are established psychotomimetics. Risk of precipitating or exacerbating psychosis is high.supported

    Landmark review of PCP pharmacology including NMDA receptor hypofunction and dopaminergic effects. s0893-133x(98)00060-8

  • Claim in safety — inconclusiveinconclusiveworking →

  • Hepatic impairment: Metabolism via polymorphic CYP enzymes (inferred from 3-MeO-PCP data) means impaired hepatic function could prolong drug exposure.supported

    CYP enzyme involvement identified. 1570159x14666161018151716

  • Claim in safety — inconclusiveinconclusiveworking →

pharmacology13 · 8 ok

  • This places 3-MeO-PCMo approximately 12-fold weaker than PCP and comparable to ketamine at the NMDA receptor.supported

    3-MeO-PCMo showed moderate NMDAR affinity comparable to ketamine, ~12-fold lower than PCP. dta.2213

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Colestock et al. (2018) characterized 3-MeO-PCMo across 46 CNS receptor targets using (+)-[³H]-MK-801 displacement in rat forebrain membrane preparationssupported

    46 CNS receptors. In vitro MK-801 binding at rat forebrain NMDAR. dta.2213

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Roth et al. (2013) demonstrated high sigma receptor affinity for the closely related 3-MeO-PCP and 4-MeO-PCP via the NIMH Psychoactive Drug Screening Program, and methoxydine — a structurally related arylcyclohexylamine — acts as an agonist at both sigma-1 and sigma-2 receptorssupported

    PCP analogues exhibited high affinities for sigma receptors. journal.pone.0059334

  • Roth et al. (2013) demonstrated high sigma receptor affinity for the closely related 3-MeO-PCP and 4-MeO-PCP via the NIMH Psychoactive Drug Screening Program, and methoxydine — a structurally related arylcyclohexylamine — acts as an agonist at both sigma-1 and sigma-2 receptorssupported

    Methoxydine acts as NMDA antagonist...and agonist at sigma-1, sigma-2, and opioid receptors. j.mehy.2013.03.030

  • The Colestock et al. (2018) screening of 46 receptors may include sigma binding data, but these values are not reported in the published abstract.supported

    Pharmacological characterization of 3-MeO-PCMo and five analogues at 46 CNS receptors. In vitro MK-801 binding at rat forebrain NMDAR. dta.2213

  • Serotonin transporter (SERT): Roth et al. (2013) found appreciable SERT affinities for methoxetamine and PCP analoguessupported

    Methoxetamine and PCP analogues showed appreciable affinity for serotonin transporter. journal.pone.0059334

  • Downstream dopaminergic effects: NMDA receptor hypofunction in prefrontal cortical interneurons disinhibits mesolimbic dopaminergic signaling — a mechanism established for PCP and its classsupported

    Landmark review of PCP pharmacology including NMDA receptor hypofunction and dopaminergic effects. s0893-133x(98)00060-8

  • Metabolic pathway data are inferred from the closely related 3-meo-pcp (same 3-methoxyphenyl-cyclohexyl scaffold, piperidine instead of morpholine), studied by Michely et al. (2017) using rat urine and human liver microsome preparations:supported

    Metabolic fate of 3-MeO-PCP and 3-MeO-PCPy in rat urine and human liver microsomes. 1570159x14666161018151716

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

receptor-pharmacology8 · 8 ok

  • Colestock et al. (2018) screened the compound at 46 CNS receptor targets using radioligand displacement assays in rat forebrain preparationssupported

    46 CNS receptors. In vitro MK-801 binding at rat forebrain NMDAR. dta.2213

  • The Ki value of approximately 253 nM places 3-MeO-PCMo approximately 12-fold weaker than PCP and in the same potency range as ketaminepartially supported

    3-MeO-PCMo showed moderate NMDAR affinity comparable to ketamine, ~12-fold lower than PCP. dta.2213

  • This rank order demonstrates that meta-position substitution on the phenyl ring (positions 3-) preserves or enhances NMDA affinity relative to the unsubstituted parent, while para-substitution (position 4-) substantially diminishes it.supported

    Pharmacological characterization of 3-MeO-PCMo and five analogues at 46 CNS receptors. dta.2213

  • 3-MeO-PCP and 4-MeO-PCP: High affinity for sigma receptors demonstrated via the NIMH Psychoactive Drug Screening Program.supported

    PCP analogues exhibited high affinities for sigma receptors. journal.pone.0059334

  • Methoxydine: Characterized as an agonist at both sigma-1 and sigma-2 receptors.supported

    Methoxydine acts as NMDA antagonist...and agonist at sigma-1, sigma-2, and opioid receptors. j.mehy.2013.03.030

  • PCP class: Sigma receptor binding is a well-established secondary pharmacological activity across the arylcyclohexylamine class.supported

    Review of sigma binding sites including PCP receptor and their role in arylcyclohexylamine pharmacology. pmid:2172677

  • The Colestock et al. (2018) 46-receptor screen may contain sigma binding data for 3-MeO-PCMo, but values beyond the NMDA receptor are not reported in the published abstract.supported

    Pharmacological characterization at 46 CNS receptors. In vitro MK-801 binding at rat forebrain NMDAR. dta.2213

  • SERT affinity has been documented for several methoxylated PCP analogues, but whether 3-MeO-PCMo possesses meaningful serotonin transporter binding has not been determinedsupported

    Methoxetamine and PCP analogues showed appreciable affinity for serotonin transporter. journal.pone.0059334

summary7 · 6 ok

  • It acts as a non-competitive NMDA receptor antagonist with a Ki of approximately 253 nM at the PCP binding site — roughly 12-fold weaker than PCP and comparable to ketaminepartially supported

    3-MeO-PCMo showed moderate NMDAR affinity comparable to ketamine, ~12-fold lower than PCP. dta.2213

  • The sole published pharmacological characterization — Colestock et al. (2018) — synthesized and screened the compound across 46 CNS receptor targets, confirming NMDA receptor antagonism as its primary mechanismsupported

    Pharmacological characterization of 3-MeO-PCMo and five analogues at 46 CNS receptors. In vitro MK-801 binding at rat forebrain NMDAR. dta.2213

  • Sigma receptor agonism — established for the closely related 3-MeO-PCP and methoxydine but not directly confirmed for 3-MeO-PCMo — may contribute additional stimulant and mood-elevating qualitiessupported

    PCP analogues exhibited high affinities for sigma receptors. journal.pone.0059334

  • Sigma receptor agonism — established for the closely related 3-MeO-PCP and methoxydine but not directly confirmed for 3-MeO-PCMo — may contribute additional stimulant and mood-elevating qualitiessupported

    Methoxydine acts as NMDA antagonist...and agonist at sigma-1, sigma-2, and opioid receptors. j.mehy.2013.03.030

  • Claim in summary — inconclusiveinconclusiveworking →

  • All toxicological inference derives from 3-MeO-PCP, where fatalities have been documented — invariably involving co-ingestion of CNS depressantssupported

    Seven deaths and one non-fatal intoxication involving 3-MeO-PCP in Sweden during March 2014 to June 2016. j.forsciint.2017.02.034

  • All toxicological inference derives from 3-MeO-PCP, where fatalities have been documented — invariably involving co-ingestion of CNS depressantssupported

    Fatal case involving 3-MeO-PCP (152 µg/L whole blood), amphetamine, and alcohol. j.jflm.2019.05.011

chemistry5 · 4 ok

  • Claim in chemistry — inconclusiveinconclusiveworking →

  • The PCMo (phenylcyclohexylmorpholine) series explored by Colestock et al. (2018) included six positional isomers and ring-substituted variants: PCMo (unsubstituted), 2-MeO-PCMo, 3-MeO-PCMo, 4-MeO-PCMo, 3,4-MD-PCMo (methylenedioxy), and 3-Me-PCMo (methyl).supported

    3-MeO-PCMo and five analogues (2-MeO-PCMo, 4-MeO-PCMo, 3,4-MD-PCMo, 3-Me-PCMo, PCMo). dta.2213

  • The methoxy group at the meta position of the phenyl ring is a key pharmacophoric element — its position influences NMDA receptor binding affinity, as demonstrated by the potency rank order across the PCMo isomer series.supported

    Pharmacological characterization of 3-MeO-PCMo and five analogues...at 46 CNS receptors. In vitro MK-801 binding at rat forebrain NMDAR. dta.2213

  • Colestock et al. (2018) synthesized and characterized it analytically (NMR, mass spectrometry) but did not report physical constants beyond spectral data.partially supported

    All compounds synthesized and characterized by chromatographic, MS, and spectroscopic techniques. dta.2213

  • Positional isomers within the PCMo series (2-MeO, 3-MeO, 4-MeO) require careful chromatographic and spectroscopic techniques to distinguish, as they share identical molecular formulae and similar fragmentation patternssupported

    All compounds synthesized and characterized by chromatographic, MS, and spectroscopic techniques. dta.2213

pharmacokinetic-detail5 · 3 ok

  • Confirmation requires gas chromatography–mass spectrometry (GC-MS) or liquid chromatography–high-resolution mass spectrometry (LC-HRMS)supported

    Detectability in urine by GC-MS and LC-HRMS. 1570159x14666161018151716

  • Metabolic data are extrapolated from Michely et al. (2017), who characterized the metabolic fate of 3-MeO-PCP and 3-MeO-PCPy (rolicyclidine analogue) using rat urine and human liver microsome incubations.supported

    Metabolic fate of 3-MeO-PCP and 3-MeO-PCPy in rat urine and human liver microsomes. 1570159x14666161018151716

  • Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

  • Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

  • Positional isomers within the PCMo series require careful chromatographic separation for unambiguous identification.supported

    All compounds synthesized and characterized by chromatographic, MS, and spectroscopic techniques. dta.2213

comparative-pharmacology4 · 3 ok

  • Direct head-to-head pharmacological comparison data for 3-MeO-PCMo exist only within the PCMo analogue series characterized by Colestock et al. (2018)supported

    Pharmacological characterization of 3-MeO-PCMo and five analogues at 46 CNS receptors. dta.2213

  • Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

  • Both compounds exhibit comparable Ki values at the NMDA receptor PCP binding site (~253 nM for 3-MeO-PCMo versus ~660 nM for racemic ketamine and ~130 nM for S-ketamine)partially supported

    3-MeO-PCMo showed moderate NMDAR affinity comparable to ketamine. dta.2213

  • The Colestock et al. (2018) study provides the only published intra-series comparison:supported

    Pharmacological characterization of 3-MeO-PCMo and five analogues at 46 CNS receptors. dta.2213

history4 · 1 ok

  • The compound emerged on online research chemical markets in the mid-2010s as one of a proliferating series of arylcyclohexylamine novel psychoactive substances (NPS) derived from phencyclidine and its methoxylated analoguessupported

    Pharmacological characterization of 3-MeO-PCMo and five analogues...All compounds synthesized and characterized. dta.2213

  • Claim in history — not_supportednot supportedworking →

  • Claim in history — inconclusiveinconclusiveworking →

  • Claim in history — inconclusiveinconclusiveworking →

neuroscience3 · 3 ok

  • The following mechanisms are inferred from the compound's confirmed NMDA receptor antagonism and from established neuroscience of PCP-site NMDA antagonists.supported

    3-MeO-PCMo showed moderate NMDAR affinity comparable to ketamine, ~12-fold lower than PCP. dta.2213

  • PCP and ketamine produce measurable reductions in thalamocortical connectivity, dissociating sensory input processing from higher-order cortical integrationsupported

    Landmark review of PCP pharmacology including NMDA receptor hypofunction and dopaminergic effects. s0893-133x(98)00060-8

  • Prefrontal disinhibition and dopaminergic activation: NMDA receptor hypofunction on GABAergic interneurons in the prefrontal cortex reduces inhibitory tone, leading to paradoxical cortical excitation and downstream disinhibition of mesolimbic dopamine release from the ventral tegmental area (VTA) to the nucleus accumbens (NAc)supported

    Landmark review of PCP pharmacology including NMDA receptor hypofunction and dopaminergic effects. s0893-133x(98)00060-8

clinical-evidence2 · 1 ok

  • Claim in clinical-evidence — inconclusiveinconclusiveworking →

  • Its only published pharmacological characterization is a forensic and analytical study (Colestock et al. 2018) motivated by its appearance on research chemical markets, not by therapeutic intent.supported

    Syntheses, analytical and pharmacological characterizations of the 'legal high' 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo). dta.2213

3Sources

15 consumed · sorted by year · feeds = sections resting on it

Sources
yearsourcetierstatusfeeds
20243-MeO-PCMo — PsychonautWikiurl:acab476d88edfe69weakconsumedcited only
2022Reports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2017–2020: A ReviewMohr ALA, Logan BK, Fogarty MF, Krotulski AJ, Papsun DM, et al. · Journal of Analytical Toxicologydoi:10.1093/jat/bkac023moderateconsumed4 sections
2019Intoxication with 3-MeO-PCP alone: A case report and literature reviewBerar A, Allain JS, Allard S, Lefevre C, Baert A, Morel I, Bouvet R, Gicquel T · Medicinedoi:10.1097/md.0000000000018295weakconsumedcited only
2019New/emerging psychoactive substances and associated psychopathological consequencesSchifano F, Napoletano F, Chiappini S, Guirguis A, Corkery J · Psychological Medicinedoi:10.1017/s0033291719001727moderateconsumed1 section
2019The risk of emerging new psychoactive substances: The first fatal 3-MeO-PCP intoxication in The Netherlandsde Jong LAA, Olyslager EJH, Duijst WLJM · Journal of Forensic and Legal Medicinedoi:10.1016/j.jflm.2019.05.011weakconsumed2 sections
2018Syntheses, analytical and pharmacological characterizations of the 'legal high' 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo) and analoguesColestock T, Wallach J, Mansi M, Filemban N, Morris H, Elliott SP, Westphal F, Brandt SD, Adejare A · Drug Testing and Analysisdoi:10.1002/dta.2213moderateconsumed9 sections
20173-MeO-PCP intoxication in two young men: First in vivo detection in ItalyBertol E, Pascali J, Palumbo D, Catalani V, Di Milia MG, Fioravanti A, Mari F, Vaiano F · Forensic Science Internationaldoi:10.1016/j.forsciint.2016.12.028weakconsumed1 section
2017A non-fatal intoxication and seven deaths involving the dissociative drug 3-MeO-PCPJohansson A, Lindstedt D, Roman M, Thelander G, Nielsen EI, Lennborn U, Sandler H, Rubertsson S, Ahlner J, Kronstrand R, Kugelberg FC · Forensic Science Internationaldoi:10.1016/j.forsciint.2017.02.034weakconsumed3 sections
2017New Psychoactive Substances 3-Methoxyphencyclidine (3-MeO-PCP) and 3-Methoxyrolicyclidine (3-MeO-PCPy): Metabolic Fate Elucidated with Rat Urine and Human Liver PreparationsMichely JA, Manier SK, Caspar AT, Brandt SD, Wallach J, Maurer HH · Current Neuropharmacologydoi:10.2174/1570159x14666161018151716moderateconsumedcited only
2016Ketamine-Induced Apoptosis in Normal Human Urothelial Cells: A Direct, N-Methyl-d-Aspartate Receptor-Independent Pathway Characterized by Mitochondrial StressBaker SC, Shabir S, Georgopoulos NT, Southgate J · American Journal of Pathologydoi:10.1016/j.ajpath.2015.12.014moderateconsumed1 section
2015Phencyclidine analog use in Sweden--intoxication cases involving 3-MeO-PCP and 4-MeO-PCP from the STRIDA projectBäckberg M, Beck O, Helander A · Clinical Toxicologydoi:10.3109/15563650.2015.1079325moderateconsumed1 section
2013Is methoxydine a new rapid acting antidepressant for the treatment of depression in alcoholics?Coppola M, Mondola R · Medical Hypothesesdoi:10.1016/j.mehy.2013.03.030moderateconsumed3 sections
2013The ketamine analogue methoxetamine and 3- and 4-methoxy analogues of phencyclidine are high affinity and selective ligands for the glutamate NMDA receptorRoth BL, Gibbons S, Arunotayanun W, Huang XP, Setola V, Treble R, Iversen L · PLoS ONEdoi:10.1371/journal.pone.0059334moderateconsumed5 sections
1999The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia.Jentsch JD, Roth RH · Neuropsychopharmacologydoi:10.1016/s0893-133x(98)00060-8strongconsumed3 sections
1990Sigma binding sites in the brain; an emerging concept for multiple sites and their relevance for psychiatric disordersItzhak Y, Stein I · Life Sciencespmid:2172677moderateconsumed1 section
—Schedules of Controlled Substances: Placement of 3-Methoxyphencyclidine in Schedule I (Final Rule)url:f246d23d56d6c12f—unknowncited only
—Searched ClinicalTrials.gov for "3-MeO-PCMo morpholine phencyclidine" — no resultsabsenceno results—

4Docket

one filing per activity — decisions, correspondence, reports

  1. 0012026-05-09revisionRevision 1

    Initial LLM generation (v5 pipeline, wiki, prose phase)

    psx:substance/3-meo-pcmo/version/1
  2. 0022026-06-04proposal27 value proposals approved together

    one review action inferred from a shared reviewer and instant — the graph records one activity per proposal

    27 items in this filing

    • contraindication · respiratory
    • contraindication · cardiovascular
    • contraindication · neurological
    • contraindication · hepatic
    • contraindication · psychiatric
    • contraindication · pregnancy_breastfeeding
    • contraindication · metabolic
    • dose_tier · threshold
    • dose_tier · light
    • dose_tier · common
    • dose_tier · strong
    • dose_tier · heavy
    • timeline · oral · onset
    • timeline · oral · peak
    • timeline · oral · resolution
    • timeline · oral · afterglow
    • toxicity
    • dependence · full
    • withdrawal
    • tolerance
    • dosage · oral
    • duration · oral · onset
    • duration · oral · peak
    • duration · oral · offset
    • duration · oral · total
    • duration · oral · aftereffects
    psx:substance/3-meo-pcmo/proposal/contraindication/22755771-bc8f-4358-857a-6975c65217ec
  3. 0032026-06-04publicationPublication — backfill
    psx:substance/3-meo-pcmo/pub/be34f583-daa3-4c66-be79-bf5ceb13760f
  4. 0042026-10-02rulingRuling — psx:substance/3-meo-pcmo/proposal/article_section_proposals/092104b5-1ebe-4f11-91db-9bb170333b54founder
    psx:substance/3-meo-pcmo/ruling/harm-reduction-headings/092104b5-1ebe-4f11-91db-9bb170333b54
  5. 0052026-10-02rulingRuling — psx:substance/3-meo-pcmo/proposal/article_section_proposals/664825fb-50be-4965-b407-dcc0323e9d4bfounder
    psx:substance/3-meo-pcmo/ruling/harm-reduction-headings/664825fb-50be-4965-b407-dcc0323e9d4b
  6. 0062026-10-02revisionr1.a1

    no edit summary recorded

    psx:substance/3-meo-pcmo/version/2
  7. 0072026-10-02publicationPublication — publishagent-psx
    psx:substance/3-meo-pcmo/pub/af429061-042e-449f-b2b3-17727818b0a9

5Issued documents

what the notice, info card and emergency page said, by hash

Issued documents
documentcontent hashissuedfrom versionsuperseded
info_cardba24b67503fdd1407c55842a…2026-10-02 12:19Revision 2current
emergencyba304cf8bf8de5b4ec66cb2b…2026-09-04 04:27Revision 1current
info_cardcc56525ee3fa2b8d2d4f5323…2026-09-04 04:27Revision 1superseded2026-10-02
noticed64f1d67defc4c768ba3201a…2026-09-04 04:27Revision 1current